D eposition of antibody-antigen immune complexes (ICs) in tissues underlies the pathogenesis of a range of human autoimmune diseases from glomerulonephritis, systemic lupus erythematosus (SLE), arthritis, and transplantation rejection to rheumatic fever. Experimental and clinical evidence suggests that autoimmunity is a risk factor for cardiovascular disease (CVD). Here, we overview the literature that links autoimmune diseases and accelerated atherosclerosis and review our understanding of IC-induced inflammation. In particular, we discuss the contribution of the location and composition of ICs to the cellular and molecular mechanisms of disease that develop and detail the steps leading to IC-mediated leukocyte recruitment and tissue injury. The focus is on neutrophil-dependent tissue injury. Although these cells have not found a prominent place in discussions of chronic inflammatory conditions such as autoimmunity and atherosclerosis, recent literature discussed here indicates that neutrophils initiate IC-induced inflammation that in turn launches and informs the subsequent immune response. A fuller understanding of the mechanisms involved in the initiation and perpetuation of immunoglobulin G (IgG) antibody mediated inflammation may lead to the design of innovative therapeutic strategies to prevent cardiovascular complications in patients with autoimmune diseases.
Accelerated Atherosclerosis in Autoimmune Diseases
Well-controlled studies have demonstrated that autoimmunity is an independent risk factor for atherosclerotic lesions and premature myocardial infarction. 1, 2 Population-based studies in various countries have shown that CVD-associated mortality in patients with rheumatoid arthritis (RA) is 1.5 to 2.0 times higher than in control individuals. [3] [4] [5] [6] Similarly, increased rates of CVD have been reported in other forms of inflammatory arthritis, including giant cell arteritis 7 and psoriatic arthritis. 8 The risk for CVD and myocardial infarction is also pronounced in patients with SLE, a complex autoimmune disease affecting multiple organs. The Pittsburgh lupus cohort presented a 52-fold increase in cardiovascular events in young women with SLE. 9 The Framingham Heart Study risk factors contribute to CVD in patients with SLE and other autoimmune disorders, probably in a propor-tional manner. However, after statistical control for these factors, the risk for myocardial infarction in SLE patients is 10-fold and for overall CVD is 17-fold higher than in controls. 10 Patients with antiphospholipid syndrome, typically characterized by recurrent thrombosis and pregnancy loss, have increased rates of atherosclerotic lesions. The antibodies in this syndrome are directed against plasma proteins complexed to anionic phospholipids such as ␤ 2 -glycoprotein I, which is found in atherosclerotic lesions, 11, 12 and interfere with endothelial cell function. 13 Epidemiological studies have identified a number of immune markers to correlate with the development of CVD in patients with autoimmune disorders. Rheumatoid factor (IgM anti-Fc IgG antibody) has been reported to represent an independent risk for the development of CVD in patients with RA. 14 Erythrocyte sedimentation rate and vascular and intercellular cell adhesion molecule serum levels, markers of immune cell activation, correlate with the development of atherosclerosis in RA patients. 15 Similarly, in patients with SLE, serum levels of cytokines and chemokines like interleukin-6, monocyte chemoattractant protein-1, intercellular cell adhesion molecule, vascular endothelial growth factor, soluble CD40 ligand, and tumor necrosis factor-␣ correlate in cross-sectional studies with the development of CVD. 3, 16 In addition to clinical evidence, animal studies provide strong arguments that autoimmunity predisposes to accelerated atherosclerosis. Vessel inflammation and fatty lesions are increased in the lupus-prone mouse MRL/lpr, 17 and an increased rate of myocardial infarcts has been noted in male NZWϫBXSB mice, also prone to developing lupus. 18 Similarly, B6.Fas lpr/lpr mice (Fas-deficient mice) and B6.Sle1.2.3 mice (triple-congenic mice in which 3 Sle loci from the NZM2410 mouse have been transferred to the B6 mouse) display increased rates of CVD. 19 Evidence that ICs accelerate atherosclerosis in animal models has also been provided. Repeated immunization with protein antigens that lead to IC formation accelerated diet-induced atherosclerosis in rabbits and mice. 20 A deficiency in Fc␥Rs, receptors for monomeric and complexed IgG, limited development and progression of atherosclerosis in mice. 21 Moreover, immunoglobulin therapy, used to treat immune-mediated disorders for Ͼ25 years, 22 markedly suppressed atherosclerosis through immu-nomodulation of Fc␥Rs. 23 Some clues on how ICs may be atherogenic are emerging. Oxidized lipids and antibodies to oxidized low-density lipoproteins (LDLs) are elevated in SLE, 11, 12 and macrophages incubated with oxidized LDL IC demonstrate enhanced uptake, cholesteryl ester accumulation, and foam cell formation in vitro compared with native LDL. 24 Uptake through Fc␥Rs was associated with macrophage activation and release of cytokines, which are characteristics of atherosclerotic lesions. 25 The independent contribution of SLE and IgG ICs to the development of atherosclerosis is further supported by the observation that apolipoprotein E (ApoE) and Fas lpr/lpr (lupus-prone mice) double-deficient B6 mice spontaneously develop lupus-like disease and develop far more atherosclerotic lesions than mice deficient in ApoE or Fas alone. Elevated anti-oxidized phospholipid IgG antibody levels in the double-deficient mice were associated with increased IgG deposition in the aorta intima and significantly correlated with atherosclerotic lesion area. 26 Together these data suggest that autoantibodies play a role in the pathogenesis of atherosclerosis.
Chronic systemic inflammation, endothelial dysfunction, and immune dysregulation observed in SLE and RA are known to also promote atherosclerosis. 11 Indeed, the cholesterol-lowering drug HMG-CoA reductase inhibitor simvastatin, also known for its antiinflammatory effects, reduced the atherosclerotic lesion area and proinflammatory cytokine production in mice with lupus-like features independently of effects on cholesterol levels. 27 LDL and cholesterol may not contribute differently in SLE patients and in normal controls, but disease duration, lack of aggressive treatment with immunosuppressants, 1 and the high levels of homocysteine 2 contribute independently to early CVD. These clinical data point to an independent contribution of SLE immune features to the development of CVD. Consistent with this, studies in animal models show that transfer of bone marrow cells from B6.Sle1.2.3 mice (which readily develop lupus and CVD) to the B6.LDLR Ϫ/Ϫ mice (an accepted model of atherosclerosis) increased the rate of formation of atherosclerotic lesions that were heavily infiltrated by CD3 ϩ cells. 28 In a human artery severe combined-immunodeficiency mouse chimera, adoptively transferred human T cells instigated arterial wall inflammation only when wall-embedded dendritic cells (DCs) were conditioned with Toll-like receptor (TLR) ligands. 29 If the transferred T cells produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), it may bind to DR5 (a TRAIL receptor) on the surface of smooth muscle cells and cause their apoptotic death. 30 Accordingly, activated T cells, probably displaying adhesion molecules, 31 present in patients with SLE may enter vessels in which the resident DCs have been activated and contribute significantly to the expression of vessel pathology in the form of atherosclerotic plaques. Macrophages may differentiate in the presence of lupus serum to DCs 32 and may account for the increased presence of DCs in the vessel walls of SLE patients.
Less well appreciated is the contribution of neutrophils to atherosclerotic lesion development in the context of autoimmunity. Neutrophils are abundant in joint lesions of RA patients and play a prominent role in RA development in mouse models. 33 Neutrophils are also present in renal tissue of lupus nephritis patients. 34 Although a role for neutrophils in murine lupus nephritis models has not been directly shown, they contribute significantly to immune-mediated anti-glomerular basement membrane (GBM) nephritis in mice, as discussed later in this review. Murine anti-GBM nephritis and SLE nephritis likely share underlying mechanisms because there is concordance in the molecules required for progression of renal disease in these 2 models. 35 Polymorphonuclear neutrophils (PMNs) have been detected in human atherosclerotic plaques, 36 albeit they are fewer compared with other immune cell types. PMNs have been found in the plaque erosion or rupture on atherectomy specimens from patients with angina pectoris and myocardiac infarction, suggesting that they may contribute to plaque destabilization. Atheromatous lesions contain markers of neutrophil degranulation such as myeloperoxidase (MPO) and neutrophil proteases, indicating the presence of active neutrophils. MPO generates reactive oxygen species that promote endothelial cell apoptosis, tissue factor expression, LDL protein nitration, and lipid peroxidation, which can advance lesion development. In parallel, the peripheral blood neutrophil number is an independent risk factor and a predictor for future occurrences of cardiovascular events. Indeed, high peripheral neutrophil counts correlate with the increase in coronary disease better than any other leukocyte subset, including total white blood cell, lymphocyte, or monocyte count. 37 In animal models, neutrophils and/or monocytes were detected within atherosclerotic lesions 38 and colocalized with MPO. 39 Neutrophil depletion decreased neutrophil content and lesion size in ApoE-null mice. An inhibition of CXCR2 specifically on neutrophils decreased neutrophil accumulation in the aortic root and arch. 40 On the other hand, an antagonist for CXCL12, a chemokine that retains granulocytic precursors within the bone marrow, increased the number of neutrophils in both circulation and aortic root plaques and adventitia in ApoE-null mice. This treatment was associated with an increase in the proportion of apoptotic neutrophils, particularly on the luminal side of the atherosclerotic plaque. 40 Together, these studies suggest a causal relationship between neutrophils and its products and atherosclerotic lesion development, but definitive mechanisms by which these cells accelerate lesion formation in the context of autoimmune disorders remain unclear. Migration and activation of Fcbearing neutrophils within plaques could occur secondary to stimulation with ICs. Human Fc␥RIIA-expressing human monocytes adhere to endothelial cells covered with immobilized ICs formed with anti-oxidized LDL and LDL. 41 Furthermore, Fc␥RIIA-dependent immune cell adhesion increases the secretion of inflammatory cytokines or chemokines, which initiates vascular injury and/or recruitment of other immune cells. [41] [42] [43] TLRs have also been widely implicated in atherogenesis. TLRs, a type of pattern recognition receptor, have emerged as key components of the innate immune system. They activate multiple steps in the inflammatory reaction in response to microbial proteins, DNAs and RNAs, from either invading microbes or host-derived self-ligands associated with cell stress or death (damage-associated molecular patterns). Deficiency of TLR4, TLR2, and MyD88, an adapter molecule essential for the TLR signaling pathway, impaired disease in atherosclerosis-prone ApoE-or LDLR-deficient mouse strains. 44 TLRs also play important roles in SLE. Deficiency of both TLR7 and MyD88 decreased anti-DNA antibody levels and ameliorated SLE activity, whereas the TLR3deficient animal showed levels of anti-DNA production comparable to control animals. The effect of TLR-9 deficiency on the lupus phenotype remains poorly understood. 45, 46 In DCs, several groups have also recently shown that Fc␥RIIA facilitates the delivery of nucleic acid containing ICs, which are salient features of SLE, to intracellular vesicles containing TLR7 and TLR9, which initiate signaling. 46 -48 Human neutrophils express messenger RNA for all the TLRs except TLR3. 49 -51 Whether the Fc␥RIIA/TLR pathway described in DCs operates in neutrophils and other Fc␥RIIA bearing leukocytes such as monocytes is not known and is a fruitful area for investigation.
Ultrasonography to detect and measure intima-media thickness and electron beam computed tomography are readily used to detect preclinical atherosclerosis in patients with rheumatic and other immune disorders. 3 Although the lesions are suspected to contain a larger number of immune cells, at this point, there are no pathology reports on possible differences between the atherosclerotic lesions in patients with and without autoimmune disorders. The available epidemiological evidence urges clinicians to monitor classic CVD risk factors and advise patients appropriately. Early noninvasive detection of atherosclerotic lesions would suggest aggressive intervention with cholesterol-lowering agents, which are also known to tame the activated immune system in various autoimmune disease animal models. 52 In addition, the preceding discussion on the involvement of cellular components of the immune system in the expression of CVD in patients with autoimmune diseases calls for sharp and aggressive control of the aberrantly activated immune system.
In summary, the clinical and experimental data together signify an association between autoimmunity and atherosclerosis. There is also emerging evidence that ICs and neutrophils, prevalent features of autoimmune disease, may contribute to atherosclerotic lesion development. Thus, a better understanding of how these aspects of the innate immune response modulate inflammation may provide insights into the mechanisms of accelerated atherosclerosis in autoimmune disorders.
Reperfusion Injury in Autoimmune Disease and CVD
Advanced atherosclerosis leading to myocardial infarction or unstable angina leads to periods of ischemia, and therapeutic intervention can result in reperfusion injury. Although there are no clinical data to suggest that RA or SLE predisposes to ischemia/reperfusion injury in patients, recent work in animal models suggests that autoantibodies present in SLE may contribute to ischemia/reperfusion-induced organ injury as has been described for natural antibodies. B6.MRL/lpr mice subjected to mesenteric ischemia/reperfusion exhibited enhanced intestinal injury characterized by profound neutrophil infiltration and remote lung injury compared with nonautoimmune mice. Moreover, anti-DNA and anti-histone mono-clonal antibodies often found in sera of lupus mice reconstituted ischemia/reperfusion injury in ischemia/reperfusioninduced injury-resistant Rag-1-deficient mice that lack IgG. Anti-DNA and anti-histone monoclonal antibodies may bind to apoptotic intestinal cells, which leads to in situ IC formation, neutrophil infiltration, and neutrophil-mediated tissue damage in response to ischemia/reperfusion. Thus, SLE autoantibodies may serve as a second hit to tissue damage after reperfusion. 53 Further work is needed to assess whether this mechanism operates in the context of autoimmunity in patients.
Classification of IgG-Mediated Diseases and the Role of Neutrophils in Tissue Injury
ICs are produced continuously in response to infection, tissue injury, and foreign antigens. The Fc portion of complexed IgG or IgM can activate complement, a system of serum and cell surface proteins that interact in a cascade to generate important effectors of immunity. Antibody and complement components assemble on microbes and their toxins to target them for destruction by the innate immune system. However, when the same immune reactants interact with antigens associated with host tissue, the immune response inflicts tissue injury that extends beyond the collateral tissue damage observed during the course of an infectious challenge. An immune response to exogenous antigens can lead to discomforts such as skin irritation to potentially fatal diseases such as bronchial asthma. A response to endogenous tissue antigens can result in transfusion reactions and graft rejection when non-self-antigens are encountered and in autoimmune disease when self-antigens are recognized on host cells resulting from a break in immunologic tolerance.
Injury in antibody-mediated diseases may be categorized as type I, II, or III hypersensitivity reactions largely on the basis of the nature and location of the antigen that is the target of the response and the effector mechanisms of tissue injury (the Table) . In the clinical setting, the situation is more complex because diseases are triggered by a combination of humoral and cell-mediated factors stimulated by a single or multiple antigens, but the classification is useful because it may predict the pathological features of a given disease. Type I hypersensitivity results from the cross-linking of IgE Fc receptors on mast cells of individuals previously sensitized to the antigen. Because this review focuses on IgG ICs, type I hypersensitivity is not discussed further. In type II hypersensitivity, pathogenic IgG or IgM antibodies against cell surface or extracellular matrix antigens or exogenous "planted" antigens such as bacteria directly induce inflammation or interfere with cellular functions without overt tissue injury. In some cases, ICs fail to produce an inflammatory response because they are inaccessible to leukocytes (eg, Heymann nephritis) or the antibody-bound receptor is rapidly internalized (eg, myasthenia gravis) or is against blood elements that are efficiently removed from the circulation by the phagocyte system in the liver and spleen (eg, autoimmune hemolytic anemia). In type III hypersensitivity, ICs formed by IgG or IgM antibody against circulating antigens lodge in the capillaries, and accumulate in the surrounding basement membrane, and tissues, thus triggering an inflammatory response (the Table) . Within type II and III responses, the sequence of events in inflammation depends on the relative accessibility of the IC deposits to circulating inflammatory cells. ICs deposited intravascularly can directly engage circulating leukocytes. Perivascular and/or extravascular ICs likely engage resident cells that then release inflammatory mediators capable of activating the endothelium and their ability to recruit cells. Prototypic animal models of type II and III hypersensitivity responses are anti-GBM nephritis, also referred to as nephrotoxic serum nephritis and the reverse passive Arthus (RPA) reaction, respectively. Anti-GBM nephritis is induced by the intravenous injection of nephrotoxic serum in animals preimmunized with IgG. The antibody recognizes components of the GBM through open endothelial fenestrae, leading to renal leukocyte infiltration, extensive glomerular injury, and proteinuria that mimics features of Goodpasture syndrome in humans. 54 The RPA reaction is induced in animals by the systemic delivery of antigen and the local tissue injection of antibody. This results in IC formation in the intravascular, perivascular, and tissue compartment that triggers intense PMN infiltration, edema, and hemorrhage. Histologically, RPA lesions exhibit features of vasculitis in SLE. 55 In both type II and III responses, neutrophils are the first immune cells to be recruited. Neutrophils account for 50% to 70% of all circulating leukocytes. They are terminally differentiated cells with a relatively short half-life of 4 to 10 hours in circulation, which can be extended up to 48 hours during inflammation. They circulate in a quiescent state. However, after an insult to tissues, proinflammatory stimuli and adhesion molecules presented by the inflamed endothelium rapidly induce neutrophil rolling and adhesion to the vessel wall and subsequent transmigration into tissue. 56 Resting neutro-phils can also acquire a state of preactivation that amplifies their responsiveness to subsequent external stimuli in a process referred to as priming. This both localizes and augments the neutrophil response during inflammation. [57] [58] [59] Fundamental to an appreciation of the role of neutrophils in IC-induced injury is the principle that the arsenal of weapons that they have evolved to destroy microorganisms also play a significant role in damaging tissue. Engagement of Fc␥Rs and complement receptors triggers phagocytosis, release of enzymes and vasoactive amines, and generation of a vigorous oxidative burst. Enzymes stored in specialized intracellular granules promote hydrolytic substrate degradation as in classic lysosomes but also kill ingested bacteria and regulate various physiological and pathological processes when secreted. Among these, the antimicrobial protein MPO and proteinases are of particular interest because they are both effectors and targets of autoimmune responses. Neutrophil proteases degrade the extracellular matrix, and serve as ligands and/or modulate the function of adhesion molecules on the surface of neutrophils. 60 -62 They also inactivate antiinflammatory mediators. 63 Neutrophil-derived reactive oxygen species are directly injurious to host cells and participate in autocrine and paracrine cell signaling 64 that promotes inflammation. Finally, the transcriptional upregulation of cytokines and chemokines by activated neutrophils 65, 66 enhances neutrophil influx and the recruitment and activation of monocytes, lymphocytes, and DCs. Products from mononuclear cells in turn activate neutrophils and regulate their release from the bone marrow. 65, 67 Thus, alarm signals from the injured host and a number of proinflammatory mediators released by neutrophils together serve to marshall and coordinate the adaptive immune response. This potentially places neutrophils at the forefront of IC-mediated pathogenesis. 
Examples of Pathogenic Antibodies That Trigger Disease
Three clinical examples of autoantibodies produced in disease, anti-neutrophil cytoplasmic autoantibodies (ANCAs), anti-endothelial cell antibodies (AECAs), and anti-GBM nephritis, are discussed here. They were chosen because they target different components of the vasculature, they are featured in several types of unrelated autoimmune disorders, and studies have elegantly illustrated the point that autoantibodies generated in these type II responses are pathogenic in vivo and trigger neutrophil activation and vascular damage. ANCAs are associated with small vessel-necrotizing vasculitis with a paucity of immunoglobulin deposits in the vessel wall. The major antigen specificities of ANCAs in vasculitis are MPO (MPO-ANCA) and serine proteinase 3 (PR3-ANCA), which are components of neutrophil granules. The ANCA antigens are translocated to the cell surface upon stimulation of cells with proinflammatory cytokines. Their subsequent ligation by the F(ab 2 )Ј component of the ANCA IgG enhances neutrophil activation with the additional release of granule contents and reactive oxygen species. Cell-bound ANCA IgG may also be recognized by Fc␥R on neighboring neutrophils and trigger PMN activation. MPO-ANCAs activate MPO and to generate hypochlorous acid, which causes cytolysis of endothelial cells, thus identifying another mechanism of ANCA pathogenicity. Circulating ANCAs are reported in 90% of patients with Wegener granulomatosis, microscopic polyangiitis, and renal limited pauci-immune necrotizing and crescentic glomerulonephritis. This and additional circumstantial clinical evidence argue for a pathogenic role for ANCA in patients. 68, 69 There is also compelling in vivo data in mice in support of this postulate: Anti-MPO IgG leads to the development of nephritis and vasculitis 70 and augments the adhesion and transmigration of leukocytes across the endothelium. 71 AECAs, an entity distinct from ANCA, represent a heterogeneous group of autoantibodies to endothelial antigens and endothelial cell-planted antigens that are unified in their potential for vessel wall damage. 72 AECA lesions are induced by the adoptive transfer of IgG purified from the blood of individuals with the disease. Vasculitis-like lesions were observed with murine AECAs generated in response to immunization with AECA IgG fractions of patients with Wegener granulomatosis. Although human AECA itself was not shown to be pathogenic, mice exhibited IgG deposits in blood vessel walls as a result of the anti-anti-AECAs, which had binding properties similar to the original human AECA. 73 AECAs planted on endothelial cells can support interactions with neutrophils and can directly activate and damage the endothelium. 74 Circulating IgG against GBM can clinically produce anti-GBM disease, including glomerulonephritis, and when accompanied by pulmonary hemorrhage is known as Goodpasture syndrome. 75, 76 Renal histology typically reveals focal or segmental glomerular necrosis with destruction of the GBM and cellular proliferation leading to crescent formation. Human anti-GBM antibody binds the noncollagenous domain of type IV collagen, which is critical for the maintenance of the GBM superstructure. 77 Injection of experimentally induced human anti-GBM antibody or antibody generated in GBM-immunized animals promotes glomerulonephritis in mice. [77] [78] [79] Inflammation and damage to the vessel wall are the primary concerns because anti-GBM is accessible to the circulating leukocytes. In animals models of anti-GBM disease, recruited PMNs stay in the capillary to induce injury, likely through oxidative injury to endothelial cells, 80, 81 and do not appear to infiltrate into the subepithelial area, perhaps as a result of downregulation of chemokine receptors or reduced PMN deformability as illustrated in ANCA disease. 69 Neutrophil-induced injury to the glomerulus, the primary site of IC formation, promotes interstitial accumulation of macrophages and T cells. Studies of human biopsies revealed prominent accumulation of neutrophils within glomerular capillaries in membranous proliferative glomerulonephritis, crescentic glomerulonephritis, and lupus nephritis 34, 82, 83 that was associated with significant interstitial macrophage influx. Although anti-GBM nephritis was not included in the panel of biopsies, these reports illustrate the potential pathogenic role of neutrophils in orchestrating glomerular damage in prevalent chronic ICmediated glomerular diseases.
Characteristics of Soluble ICs That Cause Disease
Although the location of ICs is relatively well defined when antibodies are generated in situ against specific tissue antigens, as illustrated in examples of type II reactions, the fate of circulating ICs in type III responses is less predictable. Although large aggregates, or insoluble ICs, are cleared primarily by the mononuclear phagocyte system in the liver and spleen, small soluble ICs have a propensity for tissue deposition that is influenced by systemic factors, physiochemical properties of the ICs, and tissue-specific hemodynamics. Lines of evidence in humans and animal models suggest that circulating ICs first localize within the vasculature and then translocate into extravascular tissue. 84 -89 Changes in vascular permeability 84 -87 induced by cytokines and/or lipid mediators secreted by hematopoietic cells and mast cells 90 -92 are likely the initial trigger for IC deposition. In addition, ICs themselves promote vascular leakage in "permeability"-susceptible tissues such as the joint tissue, which may explain why circulating ICs can promote tissuespecific disease such as RA. 93, 94 However, permeability is likely an amplifier rather than a prerequisite for localization of arthritogenic antibody and subsequent development of RA. 95 A change in the physicochemical parameters of ICs, reflected by a change in the properties of the antigen (eg, charge, valence, or size) or the antibody (eg, subclass, size, charge, or precipitability complement-fixing abilities), can modulate the extent and location of IC deposition. 96 For example, ICs formed with an alteration in the ratio of antigen to antibody or composed of cation antigen have a higher potential to activate and bind complement C1q. 97, 98 C1q is an early component of the classic complement pathway, which promotes IC binding to endothelial cells 99,100 and extracellular matrix molecules 88, 101, 102 and modifies the lattice structure of ICs to facilitate deposition. 103 C1q also activates C3 to C3b. C3b covalently linked to ICs binds to cell surfaces. 103, 104 It also solubilizes ICs by interfering with Fc-Fc interactions, 96 which reduces their size and thus their clearance. Moreover, C3b-based convertases activate C5, which can in turn promote IC deposition. 105
Molecular Mechanisms of IC-Induced Inflammation Structural Properties of Fc␥Rs on Neutrophils
In the past several years, studies have suggested that Fc␥Rs play primary roles in diseases initiated by antibodies. 106, 107 Fc␥Rs are members of the immunoglobulin gene superfamily that binds the Fc binding domain of IgG and are widely expressed in the hematopoietic system. Currently, 2 groups of Fc␥Rs are recognized on cells of the human immune system: the high-affinity Fc␥RI, which binds monomeric IgG, and the low-affinity receptors Fc␥RII and Fc␥RIII, which preferentially bind complexed IgG. The low-affinity Fc␥Rs are present in multiple isoforms, Fc␥RII (CD32)A and B and Fc␥RIII (CD16)A and B. The Fc␥Rs are further classified as activating or inhibitory. Signals from these receptors are transmitted via immunoreceptor tyrosine-based activation (ITAM) or inhibitory (ITIM) motifs, respectively. Fc␥RI, Fc␥RIIA, and Fc␥RIIIA are activating receptors, with ITAMs present in the cytoplasmic domain of the ␣ subunit (Fc␥RIIA) or in an accessory signaling ␥ chain with which the ␣ subunit associates (Fc␥RI and Fc␥RIII). On crosslinking of the receptors by ICs, the tyrosine residues in the ITAM motifs are phosphorylated by src family tyrosine kinases, which initiate a cascade of signaling events that trigger neutrophil effector responses. The exception is the uniquely human Fc␥RIIIB, which anchors to the outer leaflet of the neutrophil plasma membrane through a glycosylphosphatidylinositol linkage and does not contain or interact with ITAMs containing adaptors. It may signal by associating with Fc␥RIIA and the integrin complement receptor 3 (Mac-1), which serve as signaling partners, and/or localizing to membrane rafts enriched in signaling molecules like Src protein kinases. The ITIM motif is present in the cytoplasmic domain of the single-chain, inhibitory Fc␥RIIB. Coligation of activating and inhibitory receptors on the same cell by ICs inhibits ITAM-triggered activation, thus providing a higher threshold for activation of cells. 107 Human neutrophils express Fc␥RI, which is upregulated on the surface by cytokines such as interferon-␥, and contain low levels of Fc␥RIIB, but this is not consistently reported. 108 -110 They also express the 2 low-affinity receptors Fc␥RIIIB and Fc␥RIIA, for which there are no genetic equivalents in mice or other mammals. 111 Fc␥RIIIB is present only in granulocytes and its surface expression and is 4-to 5-fold higher than Fc␥RIIA. Neutrophil activation by inflammatory mediators leads to rapid Fc␥RIIIB shedding and modulates Fc␥RIIA expression and function. 112 Thus, the repertoire or activity of human Fc␥Rs is regulated at an inflammatory site, which in turn may determine the magnitude of neutrophil effector responses.
Murine neutrophils express Fc␥RI and the inhibitory Fc␥RII and, unlike humans, have 2 activating receptors, Fc␥RIII and Fc␥RIV, with low and intermediate affinity for IgG, respectively. These receptors rely on the common ␥ chain for expression and signaling. 113, 114 On the basis of sequence homology of the extracellular domains, mouse Fc␥RIII resembles human Fc␥RIIA, and Fc␥RIV is the ortholog of human Fc␥RIIIA. 107 Thus, in humans, the lowaffinity human receptors are single-polypeptide molecules, with Fc␥RIIA containing its own signaling domain while the murine counterparts function as multiprotein complexes, with ligand binding and signaling functions present on separate polypeptides (Figure 1 ). Mice deficient in the ␣ subunit of specific activating receptors or the common ␥ chain are protected in acute and progressive glomerulonephritis, autoimmune skin diseases, arthritis, SLE nephritis, and the RPA reaction. 107 However, conclusions in ␥ chain-deficient mice should take into account the increasingly apparent role for the ␥ chain in the function of several receptors besides Fc␥Rs. These include integrins on platelets and leukocytes, lymphocyte antigen receptors, and cytolytic receptors on NK cells and receptors on osteoclasts. 115 Mice lacking the inhibitory Fc␥RII exhibit exaggerated responses in the aforementioned autoimmune models and develop spontaneous autoimmune kidney disease, 106, 113 indicating that Fc␥RIIB is an important regulator of its activating counterparts. Together, these data imply a central role for Fc␥Rs in modulating a spectrum of antibody-mediated diseases in the skin, kidney, lung, and joints of mice.
Role of Complement Components in IC-Mediated Responses
In addition to the strict requirement for Fc␥Rs, complement is required for IC-induced inflammation and subsequent endorgan damage. The 3 major pathways of complement activa- tion are the classic pathway, activated by ICs composed of antibody of certain isotypes; the alternative pathway, triggered by microbial cell surfaces; and the lectin pathway, activated by plasma lectin that binds mannose residues on microbes. Complement activated by all 3 pathways serves the same function. The central event is the generation of complement protein C3, which is then cleaved by C3 convertase to give rise to C3a and C3b. Further binding of C3b to C3 convertase leads to the formation of C5 convertase, which cleaves C5 to generate C5a and initiates the terminal steps of complement activation. C3b covalently attaches to surfaces of cells in which complement is activated to target them for phagocytosis by macrophages. Complement products C3a and C5a are powerful anaphylotoxins that were suspected for a long time to be the primary mechanisms by which IgG ICs trigger inflammation. Unexpectedly, mice deficient in complement C3 mounted normal IC-induced inflammatory responses in several immunological models shown to be Fc␥ chain dependent. This led to the conclusion that Fc␥Rs are the primary initiators of IgG IC-mediated inflammation. However, the importance of complement was reasserted in subsequent studies that showed that the receptor for complement component C5a is essential for IC-mediated inflammatory responses in the lung, peritoneum, 116, 117 and kidney 118, 119 of mice. In models that require C5a receptor but not complement C3, C5a may be generated by a proteolytic pathway independently of C3b. In support of this, C5a receptor blockade significantly attenuated RPA-induced neutrophil accumulation and edema in C3-deficient mice, 117 and in the genetic absence of C3, thrombin substituted for the C3-dependent C5 convertase to generate C5a. 120 C5a receptor engagement on mast cells and macrophages increases the expression of activating Fc␥Rs and suppresses the inhibitory Fc␥RIIB expression. 106 Therefore, C5a, which is a potent chemoattractant, may have a broader role in regulating the relative levels of inhibitory and activating Fc␥Rs on tissue resident cells. 121 A proximal event in the classic pathway of complement activation is the binding of the C1q component of complement C1 to the Fc region of complexed IgG or IgM. This results in the cleavage of C4 and C2 to form an enzyme complex that acts as a C3 convertase and cleaves C3. The role of early components of the classic complement pathway in autoimmune disorders such as SLE is paradoxical. Unlike the later complement activation products such as C5, which are proinflammatory, the early complement components, C1q and C4, facilitate IC disposal and the normal clearance of apoptotic cells that presumably bear SLE autoantigens. Thus, a deficiency in C1q or C4 leads to a greater susceptibility to SLE. 122, 123 On the other hand, complement C1q itself is a target of autoimmune antibodies. Anti-C1q antibodies are strongly associated with lupus nephritis and have been detected in several mouse models of SLE. 124, 125 
Mechanisms of IC-Induced Neutrophil Recruitment and Tissue Injury
Neutrophil accumulation is an early and consistent feature of IC-mediated diseases. The importance of Fc␥Rs in this process is shown by the reliable reduction in neutrophil recruitment observed in Fc␥ chain-deficient mice in various models of inflammation. 106, 113 Similarly, complement deficiency or blockade of the complement components C5a, C5aR, or C3 leads to a reduction in neutrophil accumulation in select models of IC-mediated disease. 117, 126 The prevailing paradigm is that tissue-resident cells (mast cells and macrophages) sense ICs through Fc␥Rs and complement receptors. This results in the elaboration of secondary mediators such as tumor necrosis factor-␣ and chemokines, 106 which activate endothelial cells. Adhesion receptors, together with surface-bound chemokines upregulated on the surface of activated endothelial cells, promote neutrophil recruitment through the well-described multistep process requiring selectin-mediated rolling and integrinmediated adhesion and transmigration. 56, 89, 127 Recent work suggests that this paradigm of IC-induced neutrophil accumulation may need to be revised in some cases. That is, when ICs are accessible to circulating neutrophils as in the case of in situ AECAs, anti-GBM, or soluble ICs initially deposited within the vasculature, ICs themselves may directly tether neutrophils. In vitro, Fc␥RIIIB played a primary role in neutrophil tethering to immobilized ICs under flow, but in the framework of activated endothelial cells and monomeric AECAs, Fc␥RIIA cooperated with chemokines to enhance PMN adhesion. 128, 129 In vivo, the contribution of Fc␥Rs in specific steps of neutrophil recruitment was explored by intravital microscopy, which allows the realtime analysis of the complex behavior of neutrophils within the vessel wall. Deposition of IC within the vessel wall led to Fc␥R-dependent slowing of the velocity of cells tethered to the endothelial selectin P-selectin and increased subsequent adhesion and transmigration. 88 Complement C3 played no role in these steps. Tumor necrosis factor-␣ priming of neutrophils enhanced IC-induced leukocyte recruitment, 130 which may aid in localizing neutrophil influx to sites of IC inflammation. Once soluble ICs lodged in the capillaries reach the undelying tissue, activation of resident cells and subsequently the endothelium leads to the expression of leukocyte adhesion molecules and chemokines which enhance neutrophil recruitment. 89 Fc␥Rs also played an important role in neutrophil slow rolling and adhesion when neutrophils themselves were engaged by ANCAs. 71 Once neutrophils are recruited, they can signal cytotoxic functions through Fc␥R and/or complement receptors that promote tissue damage. In vitro, engagement of Fc␥RIIA promotes phagocytosis, degranulation, and reactive oxygen species generation. Fc␥RIIIB crosslinking induces calcium mobilization and triggers degranulation and leukotriene release, 131, 132 but it has not been consistently shown to induce other neutrophil cytotoxic responses. Physiological evidence for the contribution of Fc␥R to neutrophil-dependent tissue damage has been challenging in that protection from immune-mediated disease in mice lacking activating Fc␥Rs is associated with a reduction in neutrophil recruitment, thus precluding conclusions about their role in neutrophil cytotoxicity. Recent work demonstrates that a deficiency in neutrophil Vav proteins, which signal downstream of activating Fc␥Rs, confers resistance to the RPA in the lung and skin despite normal neutrophil accumulation in these tissues. The uncoupling of neutrophil accumulation and tissue injury in these models implicates Fc␥Rs in neutrophil cytotoxicity in vivo. 133
Role of Human Fc␥Rs in IC-Induced Inflammation
Given the structural variances in Fc␥Rs between mice and humans and differences in their distribution in some cases, it is not clear how accurately studies mediated by the murine receptors alone reflect human inflammation. For example, Fc␥RIIA is present on human macrophages and platelets, whereas murine macrophages express Fc␥RIII and Fc␥RI, and murine platelets are devoid of Fc␥Rs. Recent studies have begun to address this gap in knowledge. A human Fc␥RIIA transgene under the control of its own promotor was expressed in platelets and macrophages of mice. 134 These mice developed enhanced autoimmune thrombocytopenia, collagen-induced arthritis, 135, 136 and spontaneous autoimmune disease, likely as a result of an unexplained exuberant adaptive immune response. 136 The retention of endogenous murine Fc␥Rs and thus an overall increase in the burden of Fc␥Rs in these transgenic strains could contribute to the observed phenotype. Nonetheless, these data demonstrate an important role for human Fc␥RIIA in promoting autoimmune disease in vivo.
The expression of the uniquely human Fc␥RIIA and Fc␥RIIIB selectively on neutrophils of ␥ chain-deficient mice was undertaken to elucidate the physiological role of these 2 receptors on neutrophils in vivo. Neutrophil expression of both Fc␥RIIA and RIIIB was sufficient to restore susceptibility to the RPA and anti-GBM nephritis in Fc␥ chain-deficient mice. This, in the absence of Fc␥Rs in mast cells, platelets, and macrophages, provided physiological evidence that the human Fc␥Rs on neutrophils are sufficient for inducing antibody-mediated tissue injury. Analysis of mice expressing one or the other human Fc␥R revealed that both Fc␥RIIIB and Fc␥RIIA promoted neutrophil recruitment, whereas only Fc␥RIIA induced macrophage accumulation and tissue injury. 137 To further explore the role of these 2 receptors in IC-induced neutrophil recruitment in vivo and to determine whether they have evolved differential roles in this process, the interactions of neutrophils with the vessel wall were analyzed by intravital microscopy. In the context of strictly intravascular ICs in the cremaster muscle, which was not associated with significant inflammation, 88 Fc␥RIIIB predominated in neutrophil slow rolling, adhesion, and transmigration. 137 In contrast, Fc␥RIIA supported recruitment after induction of the RPA reaction in the cremaster, 137 which induces a complex inflammatory environment of intravascular and tissue ICs, activated endothelial cells and platelets, cytokines/chemokines, and complement activation ( Figure 2 ). 89, 127, 138 These results suggest that human Fc␥RIIA and Fc␥RIIIB play contextdependent roles in IC-induced neutrophil recruitment.
What is the physiological role of Fc␥RIIIB-mediated neutrophil recruitment? Fc␥RIIIB may be required for tissue clearance of ICs under homeostatic conditions ( Figure 2) . The presence of Fc␥RIIIB on finger-like projections on the neutrophil called microvilli, 128 its fast mobility at the membrane, 112 and its weak capacity to signal tissue damage may suit it for tethering to and subsequently clearing intravascular ICs. When the Fc␥RIIIB-mediated removal of IC is overwhelmed or defective, ICs may translocate and accumulate in extravascular tissue. There, they may persist and activate resident cells to release inflammatory mediators that lead to Fc␥RIIIB shedding, enhance Fc␥RIIA-dependent recruitment and activity, and thus instigate a cycle of vessel damage that predisposes to IC-mediated disease (Figure 2 ). Indirect clinical evidence in support of the putative role of Fc␥RIIIB in IC clearance comes from recent studies demonstrating that a low expression of Fc␥RIIIB is associated with increased susceptibility to lupus nephritis and glomerulonephritis. 139 -141 What is the contribution of other well-described Fc␥Rbearing cells such as macrophages and mast cells to ICinduced disease progression? In the RPA and arthritis models, the role of mast cells is still being defined because studies on different mast cell-deficient strains, namely Kit W /Kit W-v and W/W sh mice, have reported conflicting results. Kit W /Kit W-v mice exhibit a partial to severe reduction in edema in the RPA 117, 142, 143 and fail to develop disease in the seruminduced K/BxN model of arthritis. 144 On the other hand, W/W sh mice, which are also profoundly mast cell deficient, have a normal response in the arthritis model 145 and the RPA (N.T. and T.N.M, unpublished data). It is possible that the observed basal neutropenia in the Kit W /Kit W-v mice allows phenotypic complementation by mast cells, or the recently described splenomegaly and expansion of the hematopoietic compartment (neutrophilia and thrombocytosis) in W/W sh mice 146 overshadow the need for mast cells in these models. One explanation for these results is that in the context of robust neutrophil responses/function, mast cells may not be required, whereas in the face of neutrophil insufficiency, mast cells may enhance neutrophil IC-induced functional responses by releasing neutrophil priming and activating agents. 90, 147 Macrophages are required for the development of ICmediated diseases. This is best illustrated by studies in transgenic mice with diphtheria toxin-inducible depletion of macrophages. These mice exhibit reduced numbers of glomerular crescents and renal CD4 ϩ T cells, markedly attenuated tubular injury, improved renal function, and reduced proteinuria after induction of anti-GBM nephritis. 148 Fc␥Rs on macrophages may only partially contribute to disease in this model because transgenic re-expression of the Fc␥ chain selectively in macrophages and monocytes of Fc␥ chaindeficient mice only partially restored nephritis to wild-type levels after injection of anti-GBM antisera. 149 In the human neutrophil Fc␥RIIA transgenic mice, anti-GBM-induced neutrophil accumulation preceded interstitial macrophage accumulation and tissue injury, suggesting that Fc␥R-bearing neutrophils signal macrophage recruitment into the kidney. 137 Macrophages have the capacity to induce apoptotic cell death of renal parenchymal cells and to promote epithelial cell proliferation and interstitial fibrosis. This may be achieved by modulating the balance of enzymes regulating matrix turnover and deposition and the repertoire of inflammatory cytokines in the lesion. 148
Conclusions
Patients with autoimmune diseases can exhibit accelerated atherosclerosis and advanced subclinical atherosclerosis that cannot be explained by traditional risk factors, indicating that autoimmunity is an independent risk factor for the development of CVD. Studies in mouse models of autoimmune disease and atherosclerosis support this view. The initiators of autoimmunity are diverse, but autoimmune diseases have common pathways of immune-mediated injury. Neutrophils are present in atherosclerotic lesions. Their peripheral counts are a predictor of future CVD, and the literature discussed here and in other recent reviews 90,106 strengthens the view that neutrophils, and their opsonic receptors Fc␥Rs, and complement play fundamental roles in initiating and then perpetuating IC-mediated immune responses. Studies of murine receptors have identified the Fc␥R and complement family of immunoreceptors as playing dominant roles in immunemediated inflammation in the context of a number of autoimmune diseases. Studies of mice engineered with human neutrophil Fc␥Rs suggest that Fc␥Rs on these cells are the first sensors of ICs. Their apparent role in neutrophil recruitment, a proximal event in IC-induced inflammation, could help answer one of the central questions in the field as to what triggers IC-induced inflammation. It also implies that neutrophil Fc␥Rs may be attractive therapeutic targets in IgGmediated inflammatory diseases. Many issues remain to be addressed before experimental findings can be translated into clinical medicine. First, further clarification of the roles of the human Fc␥Rs on neutrophils and other hematopoietic cell types in IC-induced immunologic responses is necessary given the significant differences in structure and distribution of Fc␥Rs between humans and other species. Furthermore, a more cogent understanding of how IgG ICs, complement, and their respective receptors intersect to coordinate IC-induced inflammation is needed.
If human neutrophil Fc␥Rs prove to be an attractive therapeutic target, then identification of molecular targets that negate Fc␥R function is required. Recent progress has been made in targeting a proximal signaling tyrosine kinase, Syk, which signals via ITAM-containing receptors. The Syk inhibitor protects against experimentally induced arthritis 150, 151 and SLE 152 in mice, and its therapeutic benefit has been shown in clinical trials for human arthritis. 153, 154 The inhibitor likely has its effects by targeting Fc␥R and a number of other Syk-dependent receptors in hematopoietic and intrinsic tissue cells. 115 Nonetheless, this type of approach is more specific than the immunosuppression regimens currently available for treatment of autoimmune disease, which are largely nonselective with significant side effects. Cell-specific neutralization of human Fc␥Rs or its downstream signaling partners would offer further specificity for potential therapeutics. For example, specific targeting of human neutrophil Fc␥RIIA would prevent autoimmune-induced tissue damage while preserving the ability of Fc␥RIIA-expressing macrophages to clear circulating ICs, which are constantly produced in autoimmune diseases. Moreover, specific targeting of Fc␥RIIA that spared Fc␥RIIIB would be desirable if Fc␥RIIIB proves to be important in the clearance of intravascular ICs during homeostasis. These may be realistic goals given the recent advent of cell type-specific silencing of proteins in leukocytes in vivo. Antibody to the hematopoietic restricted CD18 integrin LFA-1 was used to deliver small interfering RNA that silenced specific proteins in lymphocytes. 155, 156 The challenge lies in translating these approaches to neutrophils, which are short-lived cells with a high turnover rate and a propensity for activation on engagement of receptors/molecules on their surface. If this obstacle is surmounted, therapeutics can be designed to eliminate specific neutrophil functions deleterious to tissue integrity in autoimmune disease while largely preserving inflammatory responses required for host defense. This, in turn, may limit autoimmune-related inflammation and associated cardiovascular complications associated with autoimmune diseases.
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